نتایج جستجو برای: infliximab

تعداد نتایج: 7105  

2010
Sudha Visvanathan Carrie Wagner Joseph C Marini Daniel J Lovell Alberto Martini Ross Petty Ruben Cuttica Patricia Woo Graciela Espada Marco Gattorno Maria T Apaz Eileen Baildam Anders Fasth Valeria Gerloni Pekka Lahdenne Pierre Quartier Rotraud Saurenmann Suzanne Travers Alan Mendelsohn Stephen Xu Edward H Giannini Nicolino Ruperto

BACKGROUND We evaluated the effect of infliximab on markers of inflammation in patients with juvenile idiopathic arthritis (JIA). METHODS In this randomized, placebo-controlled substudy, 122 patients with JIA received infliximab 3 mg/kg + methotrexate (MTX)(n = 60) or placebo + MTX (n = 62) at weeks 0, 2, and 6. At week 14, patients receiving placebo + MTX crossed over to infliximab 6 mg/kg +...

2015
Niels Vande Casteele Reena Khanna Barrett G Levesque Larry Stitt G Y Zou Sharat Singh Steve Lockton Scott Hauenstein Linda Ohrmund Gordon R Greenberg Paul J Rutgeerts Ann Gils William J Sandborn Séverine Vermeire Brian G Feagan

OBJECTIVE Although low infliximab trough concentrations and antibodies to infliximab (ATI) are associated with poor outcomes in patients with Crohn's disease (CD), the clinical relevance of ATI in patients with adequate infliximab concentrations is uncertain. We evaluated this question using an assay sensitive for identification of ATI in the presence of infliximab. DESIGN In an observational...

Journal: :World journal of gastroenterology 2012
María Chaparro Montserrat Andreu Manuel Barreiro-de Acosta Esther García-Planella Elena Ricart Eugeni Domènech María Esteve Olga Merino Pilar Nos Mireia Peñalva Javier P Gisbert

AIM To evaluate the effectiveness of infliximab as a second-line therapy in Crohn's disease patients after adalimumab failure. METHODS A historical cohort study in a community-based gastroenterology practice evaluated Crohn's disease patients treated with infliximab (induction plus maintenance) after adalimumab failure. Patients were identified using a large Spanish database (ENEIDA). RESUL...

2009
Denis Mulleman Jean-Camille Méric Gilles Paintaud Emilie Ducourau Charlotte Magdelaine-Beuzelin Jean-Pierre Valat Philippe Goupille

INTRODUCTION Adjustment of infliximab dosage for individuals may be useful in improving therapeutic response in rheumatoid arthritis (RA). Herein, we aimed to determine whether measurement of infliximab serum concentration modifies the therapeutic decision and improves the control of disease activity. METHODS RA patients routinely treated with infliximab were included in an observational open...

Journal: :Annals of internal medicine 2007
Angela Raval Gita Akhavan-Toyserkani Allen Brinker Mark Avigan

BACKGROUND A warning for tuberculosis was added to the approved labeling for infliximab in October 2001. OBJECTIVE To describe adverse event reports of tuberculosis during infliximab therapy after labeling changes. DESIGN Case series. SETTING Spontaneous adverse event reports maintained in the Adverse Event Reporting System database in the United States. PATIENTS 130 patients with infli...

Journal: :Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2016
Valentina Petito Loris Riccardo Lopetuso Vincenzo Arena Egidio Stigliano Alma Boninsegna Stefano Bibbò Andrea Poscia Sergio Alfieri Fausto Rosa Arianna Amato Giovanni Cammarota Alfredo Papa Alessandro Sgambato Antonio Gasbarrini Franco Scaldaferri

BACKGROUND Infliximab is effective in inflammatory bowel disease through several mechanisms, possibly acting at the mucosal level. AIM To assess the role of infliximab on intestinal mucosa and whether it contributes to mucosal healing. METHODS Human colonic mucosal biopsies were incubated with or without infliximab. Cultured biopsies were evaluated for histological staining, CD68, CD3, E-ca...

2011
Emilie Ducourau Denis Mulleman Gilles Paintaud Delphine Chu Miow Lin Francine Lauféron David Ternant Hervé Watier Philippe Goupille

INTRODUCTION A proportion of patients receiving infliximab have antibodies toward infliximab (ATI), which are associated with increased risk of infusion reaction and reduced response to treatment. We studied the association of infliximab concentration at treatment initiation and development of ATI as well as the association of the presence of ATI and maintenance of infliximab. METHODS All pat...

Journal: :Annals of the rheumatic diseases 2002
E W St Clair

Infliximab is a chimeric anti-tumour necrosis factor alpha (TNFalpha) monoclonal antibody with high affinity and binding specificity for human TNFalpha. Results from several well designed, controlled clinical trials show repeated infusions of infliximab with concomitant methotrexate (MTX) treatment can reduce the signs and symptoms of rheumatoid arthritis (RA). This combination of infliximab an...

2018
Amy J. Naylor Guillaume Desanti Atif N. Saghir Rowan S. Hardy

Transgenic tumour necrosis factor alpha (TNFα)-driven models of polyarthritis such as the TNFΔARE mouse have proven to be invaluable in delineating aspects of inflammatory disease pathophysiology in humans. Unfortunately, the onset of joint destruction and inflammation in these models represents a significant detriment to breeding management. We examined whether TNFα depleting therapy 'inflixim...

Journal: :Inflammatory bowel diseases 2012
Anne Christine W Vos Manon E Wildenberg Ingrid Arijs Marjolijn Duijvestein Auke P Verhaar Gert de Hertogh Séverine Vermeire Paul Rutgeerts Gijs R van den Brink Daniel W Hommes

BACKGROUND Regulatory macrophages play an important role in wound healing and gut homeostasis and have antiinflammatory properties. Induction of this cell type (Mψ(ind) ) by the anti-tumor necrosis factor (TNF) antibodies, infliximab and adalimumab, has recently been shown in vitro. Also, the superiority of infliximab/azathioprine combination therapy over infliximab or azathioprine monotherapy ...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید